Abstract
The development of antimicrobial treatments for respiratory pathogens in cystic fibrosis (CF) has been an integral component to the increased survival of CF patients over the past fifty years. Despite significant treatment advances, however, respiratory failure secondary to chronic bacterial pulmonary infection remains the primary cause of death in CF patients. The purpose of this review is to discuss emerging pathogens (other than Pseudomonas) in CF by describing the characteristics of the organism, their clinical significance in CF, their mechanisms of antimicrobial resistance and the current treatment approaches including newer pharmaceutical modalities. This review will focus on the following pathogens: Burkholderia cepacia complex, Stenotrophomonas maltophilia, Achromobacter xylosoxidans, methicillin-resistant Staphylococcus aureus and nontuberculous mycobacteria The goal is to familiarize the reader with the challenges in treating pulmonary infections in CF caused by multi-drug resistant pathogens and to highlight some of the newer pharmaceutical treatments that are currently the focus of intense research.
Keywords: Cystic fibrosis, Burkholderia cepacia, Stenotrophomonas maltophilia, Achromobacter, respiratory pathogens, nontuberculous mycobacteria, multi-drug resistant pathogens, β-lactam drugs, chronic infection, biofilm formation
Current Pharmaceutical Design
Title: New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas
Volume: 18 Issue: 5
Author(s): Valerie Waters
Affiliation:
Keywords: Cystic fibrosis, Burkholderia cepacia, Stenotrophomonas maltophilia, Achromobacter, respiratory pathogens, nontuberculous mycobacteria, multi-drug resistant pathogens, β-lactam drugs, chronic infection, biofilm formation
Abstract: The development of antimicrobial treatments for respiratory pathogens in cystic fibrosis (CF) has been an integral component to the increased survival of CF patients over the past fifty years. Despite significant treatment advances, however, respiratory failure secondary to chronic bacterial pulmonary infection remains the primary cause of death in CF patients. The purpose of this review is to discuss emerging pathogens (other than Pseudomonas) in CF by describing the characteristics of the organism, their clinical significance in CF, their mechanisms of antimicrobial resistance and the current treatment approaches including newer pharmaceutical modalities. This review will focus on the following pathogens: Burkholderia cepacia complex, Stenotrophomonas maltophilia, Achromobacter xylosoxidans, methicillin-resistant Staphylococcus aureus and nontuberculous mycobacteria The goal is to familiarize the reader with the challenges in treating pulmonary infections in CF caused by multi-drug resistant pathogens and to highlight some of the newer pharmaceutical treatments that are currently the focus of intense research.
Export Options
About this article
Cite this article as:
Waters Valerie, New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas, Current Pharmaceutical Design 2012; 18 (5) . https://dx.doi.org/10.2174/138161212799315939
DOI https://dx.doi.org/10.2174/138161212799315939 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Food-derived bioactive peptides against chronic diseases
Chronic diseases, such as cardiovascular diseases and metabolic diseases, have become a great threat to the human health in recent decades due to the excessive food consumption and the prevalence of sedentary lifestyle. As a class of natural compounds, food-derived bioactive peptides have been demonstrated to possess great potential for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medical and Dental Implications of Down Syndrome: A Review Part 1: General and Craniofacial Characteristic
Applied Clinical Research, Clinical Trials and Regulatory Affairs Heart Failure in South America
Current Cardiology Reviews The Rise of Carbapenem-Resistant Acinetobacter baumannii
Current Pharmaceutical Design Single Photon Emission Tomography in the Diagnostic Assessment of Cardiac and Vascular Infectious Diseases
Current Radiopharmaceuticals γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes
Current Topics in Medicinal Chemistry Effect of Cardioembolic Etiology on Intravenous Thrombolysis Efficacy for Acute Ischemic Stroke
Current Neurovascular Research Novel Strategies for Combating Pathogenic Biofilms Using Plant Products and Microbial Antibiosis
Current Pharmaceutical Biotechnology Genome Variability in Gram-Positive Pathogenic Bacteria - Impact on Virulence and Evolution
Current Genomics Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets Magnetite Nanoshuttles for Fighting Staphylococcus aureus Infections: A Recent Review
Current Topics in Medicinal Chemistry Prevention of Bacterial Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets Invasive Aspergillosis: New Insights into Disease, Diagnostic and Treatment
Current Pharmaceutical Design Phytochemicals as Inhibitors of Candida Biofilm
Current Pharmaceutical Design <i>In Vitro</i> Evaluation of Immunogenicity of Recombinant OMP25 Protein Obtained from <i>Endemic Brucella</i> abortus Biovar 3 as Vaccine Candidate Molecule Against Animal Brucellosis
Protein & Peptide Letters Current Status of Molecular Imaging in Infections
Current Pharmaceutical Design Ketogenic Diet: A Promising Neuroprotective Composition for Managing Alzheimer’s Diseases and its Pathological Mechanisms
Current Molecular Medicine Brucella as a Potential Agent of Bioterrorism
Recent Patents on Anti-Infective Drug Discovery Pneumonia Due to Methicilin-Resistant Staphylococcus aureus (MRSA): A Review
Current Respiratory Medicine Reviews Biofilms and their Role in the Resistance of Pathogenic Candida to Antifungal Agents
Current Drug Targets The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued)